David Howton Biography and Net Worth

Mr. Howton joins Sarepta from Vertex Pharmaceuticals where he was the senior vice president, chief legal officer and a member of the executive team. In that capacity, Mr. Howton participated in the general management of the company and oversaw all aspects of the Vertex global legal and compliance departments. Prior to his appointment as chief legal officer in 2011, Mr. Howton served as the chief compliance officer and was responsible for designing and implementing the Vertex corporate compliance program as well as chairing the company's Corporate Compliance Committee. Mr. Howton joined Vertex in 2009 from Genentech where he served in a number of legal roles before becoming the company's chief healthcare compliance officer. Prior to joining Genentech Inc. in 2003, Mr. Howton was a member of the Sidley Austin LLP corporate healthcare practice where he advised on corporate transactions involving life science companies and provided regulatory counsel. Mr. Howton holds a B.A. from Yale University and a J.D. from Northwestern University School of Law.

What is David T. Howton's net worth?: The estimated net worth of David T. Howton is at least $1.52 million as of December 3rd, 2024. Mr. Howton owns 15,663 shares of Sarepta Therapeutics stock worth more than $1,522,287 as of March 16th. This net worth evaluation does not reflect any other assets that Mr. Howton may own. Learn More about David T. Howton's net worth.
How do I contact David T. Howton?: The corporate mailing address for Mr. Howton and other Sarepta Therapeutics executives is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. Sarepta Therapeutics can also be reached via phone at (617) 274-4000 and via email at investors@sarepta.com. Learn More on David T. Howton's contact information.
Has David T. Howton been buying or selling shares of Sarepta Therapeutics?: David T. Howton has not been actively trading shares of Sarepta Therapeutics over the course of the past ninety days. Most recently, David T. Howton sold 105,122 shares of the business's stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $170.88, for a transaction totalling $17,963,247.36. Following the completion of the sale, the executive vice president now directly owns 33,151 shares of the company's stock, valued at $5,664,842.88. Learn More on David T. Howton's trading history.
Who are Sarepta Therapeutics' active insiders?: Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Claude Nicaise (Director), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?: In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 71,063 shares worth more than $10,672,909.13. The most recent insider tranaction occured on March, 12th when Director Claude Nicaise sold 2,491 shares worth more than $248,203.24. Insiders at Sarepta Therapeutics own 7.7% of the company. Learn More about insider trades at Sarepta Therapeutics.
Information on this page was last updated on 3/12/2025.

David T. Howton Insider Trading History at Sarepta Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/22/2020	Sell	105,122	$170.88	$17,963,247.36	33,151
11/22/2019	Sell	25,000	$105.00	$2,625,000.00	24,388
2/1/2019	Sell	30,000	$140.00	$4,200,000.00	31,196
7/16/2018	Sell	50,000	$136.46	$6,823,000.00	37,967
9/22/2016	Sell	7,000	$60.00	$420,000.00	28,453
9/19/2016	Sell	9,304	$50.00	$465,200.00	11,168

David T. Howton Buying and Selling Activity at Sarepta Therapeutics

Sarepta Therapeutics Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $97.19

$97.06

$100.00

50 Day Range

MA: $111.73

$97.19

$127.89

2 Week Range

Now: $97.19

$97.06

$173.25

Volume

874,067 shs

Average Volume

916,983 shs

Market Capitalization

$9.43 billion

P/E Ratio

77.75

Dividend Yield

N/A

Beta

0.79